RAINBOW2024-04-012024-06-30 RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses03Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses04Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses05Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses06Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses07Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses08Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses09Member RAINBOW2024-04-012024-06-30in-bse-fin:OneOperatingExpenses10Member RAINBOW2024-06-30 RAINBOW2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543524 RAINBOW NOTLISTED Rainbow Childrens Medicare Limited Equity 2024-04-01 2025-03-31 2024-08-13 2024-08-05 INR Millions First quarter 14:40:00 15:58:00 2024-08-13 2024-08-13 Not applicable Single segment The business of running multi-specialty pediatric and obstetrics and gynecology hospital. 2024-04-01 2024-06-30 Unaudited Consolidated 3302170000.00 119340000.00 3421510000.00 424790000.00 0.00 0.00 489980000.00 181620000.00 341430000.00 1450160000.00 2887980000.00 533530000.00 0.00 533530000.00 156530000.00 -20280000.00 136250000.00 0.00 397280000.00 0.00 0.00 0.00 0.00 397280000.00 1030000.00 398310000.00 395330000.00 1950000.00 396360000.00 1950000.00 1015020000.00 10 3.89 3.89 0.00 0.00 3.89 3.89 1). The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ( the Company ), and its subsidiaries (the Company and its subsidiaries together referred to as the Group ) which have been prepared in accordance with Indian Accounting Standards ( Ind AS ) prescribed under section 133 of Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issues by the Securities and Exchange Board of India ( SEBI ) were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 August 2024. The Statutory Auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon. 2). The consolidated figures for the fourth quarter ended 31 March 2024 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year. 3). Final dividend for the financial year 2023-24 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.64 million was approved by the shareholders at the 26th Annual General Meeting held on 30 July 2024 and the same was paid on 30 July 2024. 4). During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee’s reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022. The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between the Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted with securities premium as per Companies Act , 2013. Details of utilisation of IPO proceeds: Refer PDF of Results. * During the financial year 2023-24, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per the Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table above. After this change amount to be utilised for General corporate purposes is Rs. 576.10 million. Net IPO proceeds which were unutilised as at 30 June 2024 amounting to Rs. 200.92 million (column E) were temporarily invested in fixed deposits and held in current account with banks. For Note no. 5 to 9: Refer PDF results Business promotion and advertisement 67320000.00 Canteen expenses 66190000.00 Contract wages 85790000.00 Housekeeping expenses 21110000.00 Lab and investigations 37640000.00 Other Expenses 130780000.00 Power and fuel 78570000.00 Professional fees to doctors 849640000.00 Rates and taxes 39710000.00 Repairs and maintenance 73410000.00 Re-measurement gain/(loss) on defined benefit obligation 1340000.00 1340000.00 310000.00 0.00